Published in J Virol on January 10, 2007
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog (2007) 1.56
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol (2009) 1.19
HCV drug discovery aimed at viral eradication. J Viral Hepat (2009) 1.19
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol (2009) 1.14
Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol (2009) 1.13
Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol (2008) 1.12
Hepatitis C virus infection in phenotypically distinct Huh7 cell lines. PLoS One (2009) 1.10
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol (2008) 1.09
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol (2009) 1.04
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J (2009) 1.01
Human SCARB2-mediated entry and endocytosis of EV71. PLoS One (2012) 0.98
Lipid metabolism and HCV infection. Viruses (2010) 0.96
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology (2010) 0.94
Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study. BMC Med Genet (2010) 0.93
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog (2010) 0.89
Mechanisms of viral entry: sneaking in the front door. Protoplasma (2010) 0.88
Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis. Hepat Med (2011) 0.86
Phosphoinositides in the hepatitis C virus life cycle. Viruses (2012) 0.86
Permissiveness of human hepatoma cell lines for HCV infection. Virol J (2012) 0.86
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol (2015) 0.85
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. J Virol (2014) 0.83
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One (2012) 0.83
Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother (2012) 0.81
Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry. Virol J (2009) 0.81
Bile acids promote HCV replication through the EGFR/ERK pathway in replicon-harboring cells. Intervirology (2011) 0.78
Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model. J Biol Chem (2015) 0.77
Natural killer cell function and dysfunction in hepatitis C virus infection. Biomed Res Int (2014) 0.77
Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. Scientifica (Cairo) (2012) 0.77
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol (2014) 0.76
The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. PLoS One (2014) 0.76
Update on the Development of Anti-Viral Agents Against Hepatitis C. J Clin Transl Hepatol (2013) 0.75
Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display. Antimicrob Agents Chemother (2010) 0.75
Roles of lipoprotein receptors in the entry of hepatitis C virus. World J Hepatol (2015) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (1996) 8.29
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A (2006) 6.87
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis (1981) 3.74
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest (2001) 2.85
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem (2003) 2.82
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (1993) 2.36
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem (2005) 2.31
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A (2003) 2.21
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol (2000) 2.03
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 2.02
The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol (2001) 1.75
The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J (2006) 1.52
SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J Biol Chem (1998) 1.38
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol (2006) 1.31
Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem (2005) 1.30
The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int J Biochem Cell Biol (2004) 1.26
High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem (2004) 1.21
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol (2006) 1.17
High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif. J Biol Chem (2005) 1.17
ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res (2002) 1.16
Dimerization of the scavenger receptor class B type I: formation, function, and localization in diverse cells and tissues. J Lipid Res (2003) 1.07
Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum. J Biol Chem (2003) 1.07
Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI. Biochim Biophys Acta (2005) 1.05
Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux. Biochem J (2004) 0.93
SR-BI and protein-protein interactions in hepatic high density lipoprotein metabolism. Rev Endocr Metab Disord (2004) 0.92
Transcription factor sterol regulatory element binding protein 2 regulates scavenger receptor Cla-1 gene expression. Arterioscler Thromb Vasc Biol (2004) 0.82
L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles. J Gen Virol (2006) 0.78
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 4.84
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One (2008) 2.18
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis (2008) 2.01
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol (2007) 1.87
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut (2014) 1.70
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation (2009) 1.65
Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range. J Biomed Opt (2012) 1.62
Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics (2011) 1.62
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J (2006) 1.52
Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol (2004) 1.51
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin Chem (2009) 1.48
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Liver receptor homolog 1 controls the expression of the scavenger receptor class B type I. EMBO Rep (2002) 1.42
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (2012) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res (2008) 1.35
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol (2010) 1.31